LES names 2026 Deals of Distinction winners

The Licensing Executives Society announced its 2026 Deals of Distinction Awards on Oct. 19 in San Diego, recognizing licensing and commercialization deals involving Nike, IBM, NIH, AstraZeneca and Los Alamos National Laboratory. The winners highlight major partnerships across brands, tech, life sciences and physical sciences, including an FDA-approved treatment for Menkes disease and a blockchain patent acquisition.

Why it matters: - The awards spotlight licensing deals that created new products, cleared major regulatory milestones or changed ownership of valuable intellectual property. - LES says the winning agreements solved business problems creatively and represented major shifts within their sectors.

What happened: - The Licensing Executives Society presented its 2026 Deals of Distinction Awards on Oct. 19, 2026, during the LES Annual Meeting Business Luncheon in San Diego. - The program is in its 22nd year and recognizes standout licensing and business deals across five industry sectors. - Winners included Nike and SKIMS, IBM and Circle, the National Institutes of Health and Cyprium Therapeutics, AstraZeneca and CSPC Pharmaceutical Group, and Los Alamos National Laboratory and Advent Technologies.

The details: - Nike and SKIMS won in Brands as a Business for launching NikeSKIMS, a long-term jointly built brand. - NikeSKIMS is Nike's first new brand developed with an outside partner. - LES said the NikeSKIMS structure offers a third model beyond a traditional license or a limited-edition collaboration. - IBM and Circle won in High-Tech after Circle acquired IBM's blockchain patent portfolio of more than 680 patent families and nearly 1,000 issued patents. - The IBM-Circle deal made Circle the largest holder of blockchain patents in the United States. - The transaction closed in about 10 days. - NIH and Cyprium Therapeutics won in Industry-University-Government Interface for a license and research collaboration that led to FDA approval of ZYCUBO®. - ZYCUBO® is the world's first treatment for Menkes disease, a rare and degenerative pediatric disorder. - AstraZeneca and CSPC Pharmaceutical Group won in Life Sciences for a strategic collaboration on eight next-generation programs for obesity and type 2 diabetes. - The AstraZeneca-CSPC collaboration includes an upfront payment of about $1.2 billion and a total potential value of $18.5 billion. - Los Alamos National Laboratory and Advent Technologies won in Physical Sciences for commercializing the lab's Ion Pair membrane electrode assembly technology. - The technology improves hydrogen fuel cell energy production by 60%, lowers manufacturing costs and widens the operating temperature range. - Nike said in a statement that NikeSKIMS brings together two brands with a shared belief in sport and a bold vision for serving athletes. - Tom Mavrakakis of IBM said the High-Tech deal reflected teamwork on both sides. - Steven M. Ferguson, CLP, of NIH said children with the disease now have an FDA-approved option and the potential to live longer. - Ratan Bhat, global head of business development for BioPharma at AstraZeneca, said the company and CSPC built a strong relationship and needed the partnership to move faster than either company could alone. - Marc Witkowski, commercialization manager at Los Alamos National Laboratory, said the award reflects years of close collaboration between researchers and technology transfer professionals. - LES said the awards honor agreements that are innovative, solve business problems and represent "seismic events" in their sectors.

Between the lines: - The winners show how licensing is moving beyond simple royalty deals into deeper co-development, patent consolidation and commercial partnerships. - Several of the deals combine strategic control with speed, scale or regulatory value, which can matter as much as the underlying IP. - The selection also shows how universities, government labs and life sciences companies are using licensing to turn research into products with measurable market impact.

What's next: - LES will continue using the annual awards to highlight deals that shape innovation strategy across industry sectors. - The recognized partnerships may serve as templates for future licensing structures in consumer brands, biotech, energy and advanced technology. - More information is available in LES's announcement.